Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - pemetrexed as disodium hemipentahydrate - powder for concentrate for solution for infusion - pemetrexed as disodium hemipentahydrate 500 mg - pemetrexed - pemetrexed s.k. in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. pemetrexed s.k. in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed s.k. is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed s.k. is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - mometasone furoate (as monohydrate); olopatadine as hydrochloride - nasal spray, suspension - mometasone furoate (as monohydrate) 25 mcg/delivered dose; olopatadine as hydrochloride 600 mcg/delivered dose - mometasone, combinations - ryaltris is indicated in adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - bimatoprost - ophthalmic solution - bimatoprost 0.3 mg / 1 ml - bimatoprost - reduction of elevated intraocular pressure in chronic open angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - erlotinib hydrochloride - film coated tablets - erlotinib hydrochloride 100 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib s.k. is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib s.k. is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib s.k. is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib s.k. is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 150 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib s.k. is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib s.k. is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib s.k. is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib s.k. is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - erlotinib hydrochloride - film coated tablets - erlotinib hydrochloride 25 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib s.k. is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib s.k. is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib s.k. is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib s.k. is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - salmeterol as xinafoate 50 mcg; fluticasone propionate 250 mcg - salmeterol and other drugs for obstructive airway diseases - flusalmer sk is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate . flusalmer sk is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who havesignificant symptoms despite regular bronchodilator therapy.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - salmeterol as xinafoate 50 mcg; fluticasone propionate 500 mcg - salmeterol and other drugs for obstructive airway diseases - flusalmer sk is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate . flusalmer sk is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who havesignificant symptoms despite regular bronchodilator therapy.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 10 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 2.5 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.